ArticleJournal of molecular histology2025
Renoprotective and antihypertensive mechanism of action of Clinacanthus nutans bioactive polysaccharides by suppression of reactive oxygen species/ nuclear factor/ matrix metalloproteinase (ROS/NF-ΚB/MMP-9) and upregulation of endothelial nitric oxide synthase/nitric oxide (eNOS/NO) pathways.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinacanthus nutans (C. nutans) Lindau, is classified as a top herb which are investigated for different biological activities like antioxidant, anti-inflammatory and vasodilatory effects. Hitherto, no dedicated study has been investigated on the role of C. nutans in L-NAME [N(ω)-nitro-L-arginine methyl ester] in-vivo rat model to explore its antihypertensive and renoprotective mechanism by modulating the ROS/NF-κB/MMP-9 pathways both globally in the plasma as well as locally in the kidney by using in-vitro expression study. Present study hypothesized that bioactive polysaccharides leaves of the alcoholic extract of C. nutans (CNBP) could improve the functions of the kidney by its antioxidant, anti-inflammatory, antihypertensive actions by suppression of ROS/NF-κB/MMP-9 and upregulation of eNOS/NO pathways in the plasma and kidney. Thirty male Sprague-Dawley (SD) rats (n = 6) were randomised into five groups namely: Control (C), L-NAME (L) administered in drinking water, L-NAME + 500 mg/kg of C. nutans bioactive polysaccharides (CNBP) (LCN500), L-NAME + 1000 mg/kg of CNBP (LCN1000) and L-NAME + 2000 mg/kg of CNBP (LCN2000) respectively. All treatments were continued for the period of 14 days and physiological data like water intake, urine output, body weight was collected on days 0, 7 and 14. Acute in-vivo study was performed after cannulation of the femoral and carotid arteries where renal cortical blood perfusion (RCBP) was measured along with pulse wave velocity (PWV). Plasma and renal malondialdehyde (MDA), tumour necrosis factor-α(TNF-α), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), intercellular adhesion molecule-1 (ICAM-1), nitric oxide synthase-1 (NOS1) and superoxide dismutase (SOD) were measured. Histopathological studies were done on the kidney tissue at the termination of experiment. Administrations of L-NAME to L group for 14 days resulted in significantly reduced levels of SOD and NOS while significantly elevated levels of MDA, TNF-α, IL-6 and MMP-9 in both plasma and kidney tissue when compared to control group (C). Conversely, treatment of 500, 1000 and 2000 mg/kg of CNBP has significantly reversed the values when same was compared to normal control ( C) group. Administration of L-NAME to L group for 14 days caused significantly increased systolic blood pressure (SBP) and arterial stiffness by increasing the pulse wave velocity (PWV) along with reduced creatinine clearance and renal cortical blood perfusion (RCBP) when compared to C group. Nevertheless, treatment of 500, 1000 and 2000 mg/kg CNBP has significantly reduced the SBP and PWV and raised the creatine clearance and RCBP functions when compared to (L) group. This study devised with the novel findings of 14 days CNBP treatment has suppressed ROS/TNF-α/MMP-9 pathway in the plasma and kidney which is pathological pathway for the kidney injury and hypertension while upregulated eNOS/NO pathways in plasma and kidney which is renoprotective and antihypertensive pathway in L-NAME rat model of hypertension and kidney injury.
Indexed as
Identifiers
40580398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.